Drugs / Acitretin
Acitretin
also known as
Acitretin 25Mg Cap · Acitretina · Acitretine · Etretin · Neotigason · RO 10-1670 · RO 10-1670/000 · Soriatane · +1 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | SORIATANE | — | 1996-10-28 | fda.gov ↗ |
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03753867 | Jan → May 2019 | HIV infectious disease | Ottawa Hospital Research Institute | Withdrawn | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02715960 | Dec 2015 → Dec 2017 | psoriasis | Central South University | Unknown | No outcome recorded |
| Phase 2 | NCT02050321 | Dec 2013 → Dec 2014 | melanoma | University of Arizona | Terminated | No outcome recorded |
| Phase 2 | NCT00156247 | Sep 2005 → Mar 2009 | psoriasis | University of Medicine and Dentistry of New Jersey | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01545284 | Mar 2012 → Jan 2014 | hand dermatosis | Innovaderm Research Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00002143 | — | HIV infectious disease, psoriasis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT06998875 | Mar → Oct 2025 overdue | primary cutaneous amyloidosis | Army Medical University, China | Recruiting | No outcome recorded |
| Phase 4 | NCT02181790 | Jun → Dec 2014 | psoriasis | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded |
| Phase 4 | NCT01299220 | Nov 2010 → Sep 2011 | exanthem | University of Pittsburgh | Withdrawn | No outcome recorded |
| Phase 4 | NCT01228409 | Oct 2010 → Dec 2011 | psoriasis | Frankel, Amylynne, M.D. | Unknown | No outcome recorded |
| Phase 4 | NCT00832364 | Oct 2009 → Mar 2010 | psoriasis | Stiefel, a GSK Company | Withdrawn | No outcome recorded |
| Phase 4 | NCT00707070 | Sep 2008 → Oct 2009 | psoriasis | University of Verona | Unknown | No outcome recorded |
| Phase 4 | NCT00488384 | Jun 2007 → Dec 2014 | squamous cell carcinoma | Günther Hofbauer | Withdrawn | No outcome recorded |
| Phase 4 | NCT00723437 | Jan 2005 → Jan 2007 | psoriasis | Istituti Fisioterapici Ospitalieri | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT04245319 | Jan 2020 → Nov 2021 | depressive disorder, hyperlipidemia, liver disorder | Cairo University | Unknown | No outcome recorded |
| — | NCT01094717 | Jan 2010 → Sep 2011 | psoriasis | University of Utah | Terminated | No outcome recorded |
| — | NCT00644384 | Feb 2003 → May 2006 | skin carcinoma | Mayo Clinic | Completed | No outcome recorded |
| — | NCT00003611 | May 2000 → Feb 2003 | epithelial skin neoplasm | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
Also used as a comparator or background therapy in 13 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05184348 Comparator | Sep 2021 → Jan 2023 | psoriasis | South Valley University | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06739551 Comparator | Dec 2024 → Mar 2025 overdue | lichen planus | Sheikh Zayed Medical College | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT01078168 Comparator | Mar 2010 → Jan 2013 | Alzheimer disease | K. Lieb | Completed | No outcome recorded |
| Phase 2 | NCT00395941 Comparator | Dec 2006 → Dec 2008 | psoriasis | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT07708480 Comparator | Dec 2024 → May 2025 | hidradenitis suppurativa | Hayat Abad Medical Complex, Peshawar | Completed | No outcome recorded |
| Phase 4 | NCT04239859 Comparator | Jan 2024 → Dec 2027 expected | psoriasis | Singapore General Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05401006 Comparator | Jun 2021 → Jun 2022 | psoriasis | South Valley University | Unknown | No outcome recorded |
| Phase 4 | NCT04537689 Comparator | Dec 2020 → Dec 2027 expected | psoriasis | Singapore General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05203354 Comparator | Sep 2018 → May 2021 | psoriasis | Mahmoud Ahmed Ali Ahmed | Completed | No outcome recorded |
| Phase 4 | NCT01443338 Comparator | Sep 2011 → Dec 2012 | psoriasis | Ministry of Health, China | Unknown | No outcome recorded |
| Phase 4 | NCT00936065 Comparator | Jul 2009 → Apr 2011 | psoriasis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT01039142 Comparator | Mar 2008 → Feb 2009 | psoriasis | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02191020 Comparator | Feb → Oct 2013 | psoriasis | Xijing Hospital | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 33 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | acitretin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00644384 ↗30 |
| Known as | Acitretin 25Mg Cap | “Drug: Acitretin 25Mg Cap” NCT05401006 ↗ |
| Known as | Acitretina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1131 ↗ |
| Known as | Acitretine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1131 ↗ |
| Known as | Etretin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1131 ↗ |
| Known as | Neotigason | ChEMBL registry synonym — accepted as the source's own label CHEMBL1131 ↗ |
| Known as | RO 10-1670 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1131 ↗ |
| Known as | RO 10-1670/000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1131 ↗ |
| Known as | Soriatane | “Acitretin will be provided to participants in the formulation Soriatane.” NCT03753867 ↗ |
| Known as | U0279 | “Drug: Acitretin (also called U0279)” NCT00832364 ↗ |
| Action | Activate | “enhancement of the α-secretase activity by acitretin” NCT01078168 ↗ |
| Modality | Small molecule | “acitretin, a synthetic retinoid” NCT00644384 ↗ |
| Route | Oral | “receive either placebo or acitretin 25 mg orally 5 days per week.” PMID 21882176 ↗ Aug 2011 |